A Pipeline Built for the Biology of Autism

Each program in our pipeline is designed to address a specific biological driver of autism symptoms—whether it’s cognition, motor coordination, or emotional regulation. Together, these assets form a modular, scalable platform with the potential to expand into ADHD, sarcopenia, and related neuroimmune conditions.

Our Targeted Strategy
for Delivering Fast, Effective Precision Symptom Relief

Each asset is mapped to a specific functional phenotype
in ASD and is structured for modular expansion

RT0307, RT2234, and RT8412 each align to a unique biological profile in ASD, targeting core symptom clusters. This same biology appears in other high-need populations, supporting expansion into ADHD, age-related decline, and inflammatory disorders.

Clinical Development Timing

Our pipeline is advancing across three parallel tracks, each built around a distinct biological domain. All programs are currently in IND-enabling studies, with first-in-human trials expected to begin in 2026.

The structure allows us to move efficiently from focused autism populations into broader neurodevelopmental and age-related conditions—while keeping safety, function, and family-centered outcomes at the core.

IND Enabling
Phase I
Phase II
Phase III
RT0307
2026
2027
TBD
RT2234
2026
2027
TBD
RT8412
2026
2027
TBD

Targeting Shared Biology Across
Autism, ADHD, and Aging

The biological pathways that drive autism symptoms—such as neuroinflammation, oxidative stress, mitochondrial dysfunction, and neurotransmitter imbalance—are also central to a wide range of other high-need conditions.
By targeting these shared mechanisms, each of our lead programs is positioned not only to meet urgent needs in autism, but also to expand into adjacent neurodevelopmental and neurodegenerative indications.

Core ASD Symptom Target
Mechanistic Rationale
Future Development Opportunities
RT0307
Cognition and executive function
Reduces oxidative stress and mitochondrial dysfunction; restores neurotransmitter signaling
Cognitive aging, long COVID brain fog, mild neurodegeneration
RT2234
Motor function and hypotonia
Modulates inflammation and improves mitochondrial and neuromuscular performance
Sarcopenia, frailty, metabolic muscle loss
RT8412
Attention, emotional regulation, and impulsivity
Targets cholinergic signaling, reduces oxidative stress and neuroinflammation
Adult and pediatric ADHD, anxiety, impulse-control disorders